Evidence map›Paper›PMID 39586983›Full record

ArticleInternational journal of hematology2025

Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.

Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Eiichi Ohtsuka, Morishige Takeshita, Reiji Muto, Ilseung Choi, Hiromi Iwasaki, Asahi Ito and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yuma Sakamoto *Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan. syuma@med.kawasaki-m.ac.jp.
Takashi Ishida *Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ayako MasakiDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan.
Takayuki MuraseDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan.
Eiichi OhtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Morishige TakeshitaDepartment of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Reiji MutoDepartment of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Ilseung ChoiDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Hiromi IwasakiDepartment of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Asahi ItoDepartment of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Shigeru KusumotoDepartment of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Nobuaki NakanoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Masahito TokunagaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Kentaro YonekuraDepartment of Dermatology, Imamura General Hospital, Kagoshima, Japan.
Yukie TashiroDepartment of Pathology, Imamura General Hospital, Kagoshima, Japan.
Youko SuehiroDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Shinsuke IidaDepartment of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Atae UtsunomiyaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Ryuzo UedaDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroshi InagakiDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan. hinagaki@med.nagoya-cu.ac.jp.

Funding

Grant-in-Aid for Challenging Research (Exploratory) 21K19900Grant-in-Aid for Scientific Research (B) 22H02918Grants-in-Aid for Early-Career Scientists 22K15426Grants-in-Aid for Scientific Research (C) 24K11570Grants-in-Aid from the Japan Agency for Medical Research and Development 21ae0101074h0001Grants-in-Aid from the Japan Agency for Medical Research and Development 22ae0101074h0001
6 · The paper itself

Abstract

Here, we investigated the clinical significance of NOTCH1 and FBXW7 alterations for adult T-cell leukemia/lymphoma (ATLL) treatment outcomes. NOTCH1 alterations were identified in 37 (14.4%) of 257 patients, of which 33 were single nucleotide variants/insertion-deletions in the PEST domain, and 7 were in the heterodimerization or LIN-12/Notch repeats domains. FBXW7 alterations were observed in nine ATLL patients (3.5%). For patients without allogeneic hematopoietic stem cell transplantation (HSCT), NOTCH1, but not FBXW7, alterations were significantly and independently associated with worse overall survival (median OS 0.5 years, 95% confidence interval [CI] 0.4-0.5 years for 27 patients with NOTCH1 alterations vs 1.8 years, 95% CI 1.3-2.2 years for 170 patients without). Also, for patients receiving mogamulizumab, but not allogeneic-HSCT, NOTCH1, but not FBXW7, alterations were significantly associated with worse survival (median survival from the first dose of mogamulizumab 0.4 years, 95% CI 0.3-0.5 years for 12 patients with NOTCH1 alterations vs 1.4 years, 95% CI 0.9-2.0 years for 87 without). In contrast, NOTCH1 alterations had no significant impact on survival of patients who did receive allogeneic-HSCT. Thus, mogamulizumab-containing treatment was unable to overcome treatment refractoriness of ATLL with NOTCH1 alterations. Therefore, patients with NOTCH1 alterations are recommended for allogeneic-HSCT.

Indexed as

F-Box-WD Repeat-Containing Protein 7Leukemia-Lymphoma, Adult T-CellMutationReceptor, Notch1AdultAgedClinical RelevanceFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPrognosisTreatment OutcomeYoung AdultF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanNOTCH1 protein, humanReceptor, Notch1Adult T-cell leukemia/lymphomaFBXW7Hematopoietic stem cell transplantationMogamulizumabNOTCH1

Identifiers

PMID39586983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.